CAI
Caris Life Sciences, Inc. Common Stock
About: Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
–
Funds holding %
of 7,302 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for CAI.
Financial journalist opinion
Based on 10 articles about CAI published over the past 30 days
Positive
Seeking Alpha
10 hours ago
U.S. IPO Weekly Recap: Sizable Precision Medicine And Insurance IPOs Raise A Combined $902 Million
A handful of IPOs and blank checks priced in the short holiday week, led by two sizable issuers. Two smaller IPOs also priced this past week. One IPO is currently scheduled to list in the week ahead, although some small names may also join the calendar throughout the week.
Positive
Seeking Alpha
2 days ago
Caris Life Sciences: Momentum Returns In The IPO Market
Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine, but remains deeply unprofitable despite narrowing losses. The IPO was strong, with shares surging post-offering and the company now trading at a steep 15-16x sales multiple, reflecting high investor expectations. While revenue growth is impressive and losses are shrinking, the valuation is too rich for my taste, given the ongoing substantial losses and business risks.
Neutral
Fast Company
4 days ago
Caris Life Sciences IPO: All eyes on the stock price today as the AI cancer care firm makes its Nasdaq debut
On Wednesday morning, the cancer diagnostics biotech firm Caris Life Sciences rang Nasdaq's opening bell in New York, marking the company's awaited initial public offering.
Positive
Market Watch
4 days ago
This ‘AI TechBio' company goes public as IPO demand spreads to biotech
Shares of Caris Life Sciences soared in their public debut Wednesday, as investors bought into the company's business of molecular profiling and drug research using artificial intelligence.
Positive
Market Watch
4 days ago
Caris Life Sciences Shares Rise Following IPO
The biotechnology company started trading at $27 each on Wednesday afternoon, a day after the company's IPO was priced at $21 a share. The stock was recently up 26% and trading at $26.48.
Positive
Reuters
4 days ago
Sixth Street-backed Caris Life valued at $7.66 billion in strong Nasdaq debut
Caris Life Sciences' shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor appetite for new listings in 2025.
Positive
CNBC Television
4 days ago
Caris Life Sciences CEO on IPO debut, using AI to fight against cancer
David Dean Halbert, Caris Life Sciences chairman, founder and CEO, joins 'Squawk Box' to discuss the company's IPO debut, how the company uses AI technology to help diagnose and treat cancer,
Positive
Reuters
5 days ago
Caris Life raises $494 million in US IPO
Caris Life Sciences raised $494.1 million in its Nasdaq initial public offering, the cancer diagnostic firm said on Tuesday, amid a rebound in the IPO market.
Neutral
24/7 Wall Street
1 week ago
June IPOs to Watch Closely
It's looking like it could be a fairly hot June for IPOs as a handful of firms debut on the public markets for the very first time.
Negative
Seeking Alpha
3 weeks ago
Caris Life Sciences Seeks IPO On Revenue Growth And High Operating Losses
Caris Life Sciences has filed to raise $100 million in a U.S. IPO, although the final amount may be higher. CAI operates in the precision medicine information market for the treatment of cancer and wants to ultimately expand into other disease conditions. The company faces significant competition, high debt, payer concentration risk.
Charts implemented using Lightweight Charts™